178 related articles for article (PubMed ID: 10199946)
1. Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein.
De Moerloose B; Van de Wiele C; Dhooge C; Philippé J; Speleman F; Benoit Y; Laureys G; Dierckx RA
Eur J Nucl Med; 1999 Apr; 26(4):396-403. PubMed ID: 10199946
[TBL] [Abstract][Full Text] [Related]
2. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients.
Vecchio SD; Ciarmiello A; Potena MI; Carriero MV; Mainolfi C; Botti G; Thomas R; Cerra M; D'Aiuto G; Tsuruo T; Salvatore M
Eur J Nucl Med; 1997 Feb; 24(2):150-9. PubMed ID: 9021112
[TBL] [Abstract][Full Text] [Related]
3. Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET?
Yokogami K; Kawano H; Moriyama T; Uehara H; Sameshima T; Oku T; Goya T; Wakisaka S; Nagamachi S; Jinnouchi S; Tamura S
Eur J Nucl Med; 1998 Apr; 25(4):401-9. PubMed ID: 9553170
[TBL] [Abstract][Full Text] [Related]
4. The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response.
Burak Z; Ersoy O; Moretti JL; Erinç R; Ozcan Z; Dirlik A; Sabah D; Basdemir G
Eur J Nucl Med; 2001 Sep; 28(9):1341-50. PubMed ID: 11585293
[TBL] [Abstract][Full Text] [Related]
5. The role of 99Tcm-sestamibi scintigraphy in the staging and prediction of the therapeutic response of stage IV neuroblastoma: comparison with 131I-MIBG and 99Tcm-MDP scintigraphy.
Burak Z; Yüksel DA; Cetingül N; Kantar M; Ozkiliç H; Moretti JL
Nucl Med Commun; 1999 Nov; 20(11):991-1000. PubMed ID: 10572908
[TBL] [Abstract][Full Text] [Related]
6. Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression.
Moretti JL; Azaloux H; Boisseron D; Kouyoumdjian JC; Vilcoq J
Eur J Nucl Med; 1996 Aug; 23(8):980-6. PubMed ID: 8753690
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the P-glycoprotein expression by 99mTc-MIBI bone marrow imaging in patients with untreated leukaemia.
Ak I; Aslan V; Vardareli E; Gülbaş Z
Nucl Med Commun; 2003 Apr; 24(4):397-402. PubMed ID: 12673168
[TBL] [Abstract][Full Text] [Related]
8. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.
Cordobes MD; Starzec A; Delmon-Moingeon L; Blanchot C; Kouyoumdjian JC; Prévost G; Caglar M; Moretti JL
J Nucl Med; 1996 Feb; 37(2):286-9. PubMed ID: 8667063
[TBL] [Abstract][Full Text] [Related]
9. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy.
Taki J; Sumiya H; Asada N; Ueda Y; Tsuchiya H; Tonami N
J Nucl Med; 1998 Jul; 39(7):1179-84. PubMed ID: 9669390
[TBL] [Abstract][Full Text] [Related]
10. 131I-MIBG in the diagnosis of primary and metastatic neuroblastoma.
El-Maghraby T
Gulf J Oncolog; 2007 Jul; (2):33-41. PubMed ID: 20084722
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99m-MIBI imaging.
Tatsumi M; Tsuruo T; Nishimura T
Eur J Nucl Med Mol Imaging; 2002 Mar; 29(3):288-94. PubMed ID: 12002701
[TBL] [Abstract][Full Text] [Related]
12. False-negative scintigraphy with Tc-99m sestamibi in stage IV neuroblastoma.
Ozcan Z; Erenel G; Aksoylar S; Kansoy S; Burak Z; Ozkiliç H
Clin Nucl Med; 1999 Apr; 24(4):267-70. PubMed ID: 10466525
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the in vitro and in vivo properties of a (99m)Tc-labeled inhibitor of the multidrug resistant gene product P-glycoprotein.
Bergmann R; Brust P; Scheunemann M; Pietzsch HJ; Seifert S; Roux F; Johannsen B
Nucl Med Biol; 2000 Feb; 27(2):135-41. PubMed ID: 10773542
[TBL] [Abstract][Full Text] [Related]
14. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer.
Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Sinnett D; Glass DM; Peters AM
J Nucl Med; 2002 Apr; 43(4):519-25. PubMed ID: 11937596
[TBL] [Abstract][Full Text] [Related]
15. 99mTc tetrofosmin scintigraphy in acute leukaemia: the relationship between marrow uptake of tetrofosmin and P-glycoprotein and chemotherapy response.
Sükan A; Yapar Z; SAhin B; Kara O; Fuat Yapar A; CEtiner S; Kibar M
Nucl Med Commun; 2004 Aug; 25(8):777-85. PubMed ID: 15266171
[TBL] [Abstract][Full Text] [Related]
16. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
Kelly RJ; Robey RW; Chen CC; Draper D; Luchenko V; Barnett D; Oldham RK; Caluag Z; Frye AR; Steinberg SM; Fojo T; Bates SE
Oncologist; 2012; 17(4):512. PubMed ID: 22416063
[TBL] [Abstract][Full Text] [Related]
17. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
Agrawal M; Abraham J; Balis FM; Edgerly M; Stein WD; Bates S; Fojo T; Chen CC
Clin Cancer Res; 2003 Feb; 9(2):650-6. PubMed ID: 12576431
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy.
Kostakoglu L; Guc D; Canpinar H; Kars A; Alper E; Kiratli P; Hayran M; Gündüz U; Kansu E
J Nucl Med; 1998 Jul; 39(7):1191-7. PubMed ID: 9669392
[TBL] [Abstract][Full Text] [Related]
19. The value of Tc-99m-tetrofosmin scintigraphy in the assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors.
Yapar Z; Kibar M; Yapar AF; Uguz A; Ozbarlas S; Gonlusen G
Ann Nucl Med; 2003 Sep; 17(6):443-9. PubMed ID: 14575377
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
Luker GD; Fracasso PM; Dobkin J; Piwnica-Worms D
J Nucl Med; 1997 Mar; 38(3):369-72. PubMed ID: 9074520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
